Kidney cancer treatment depends on the type of cancer, whether it is confined to the kidney, and how much kidney function can be preserved. For many small, localised tumours, kidney-sparing surgery is preferred when it can remove the cancer safely. Some patients can start with regular monitoring or have the tumour treated by ablation. When kidney cancer has spread, immunotherapy and targeted medicines are often the main treatments, and the team decides whether surgery has a role and when it should be done. [1–3]
By Dr Raman Narang, Consultant Medical & Hemato-Oncologist, New Delhi
A scan done for an unrelated reason may show a small kidney mass. The first questions are whether it is likely to be cancer, whether a biopsy would change the plan, and whether it needs treatment now. If you are seeking kidney cancer treatment in Delhi, bring the original scan images as well as the written report. The images help the team judge whether the tumour can be treated while preserving the rest of the kidney.
1. What are the symptoms, risk factors, and types of kidney cancer?
Many kidney tumours are found before they cause symptoms. When symptoms occur, they can include blood in the urine, persistent pain in the side or back, unexplained weight loss, or fatigue. Visible blood in the urine deserves assessment even if it occurs only once. It can come from several parts of the urinary tract, so the evaluation may include the bladder as well as the kidneys. [1, 3]
Smoking, obesity, high blood pressure, and certain inherited conditions increase the risk of kidney cancer. A diagnosis at a young age, tumours in both kidneys, multiple tumours, or a strong family history may prompt genetic counselling. An inherited diagnosis can affect how the kidneys are monitored and may have implications for relatives. [1–3]
This page focuses on renal cell carcinoma (RCC), the most common kidney cancer in adults. Cancer that starts in the kidney’s urine-collecting system, called the renal pelvis, is often a urothelial cancer and follows a different treatment pathway. [1, 3]
| RCC subtype | Why it matters |
|---|---|
| Clear-cell RCC | The most common subtype. Much of the evidence for immunotherapy, targeted medicines, and treatment after surgery comes from patients with clear-cell disease. |
| Papillary RCC | Has its own treatment considerations. In advanced disease, cabozantinib is one option, and other approaches may be suitable depending on the pathology and clinical situation. |
| Chromophobe and rarer RCC subtypes | Treatment depends on the exact diagnosis. Expert pathology review can be particularly helpful when the report describes an unusual or unclassified tumour. |
2. How is kidney cancer diagnosed and staged?
A contrast-enhanced CT or MRI with a kidney-specific protocol helps characterise the mass and show where it sits in the kidney. Imaging also looks for extension into nearby tissues, the renal vein, or the inferior vena cava, the large vein that carries blood back to the heart. Depending on the findings, staging may include chest imaging and tests to investigate symptoms or abnormalities elsewhere. Blood tests assess kidney function and help the team plan treatment. [1–3]
A kidney mass biopsy is useful when the result would change the decision. For example, a biopsy may help clarify an uncertain mass, is generally recommended before tumour ablation, and is needed before starting systemic treatment if there is no previous tissue diagnosis. If imaging strongly suggests RCC and surgery would be recommended regardless of the biopsy result, the diagnosis may be confirmed by examining the tissue after surgery. [1, 2]
Stage describes where the cancer is and whether it has spread. Grade, when applicable to the subtype, describes how aggressive the cells look under the microscope. After surgery, the team reviews the stage, grade, subtype, and other pathology features to estimate the risk of recurrence. [1, 2]
3. When can the kidney be spared, and when is the whole kidney removed?
Partial nephrectomy removes the tumour while preserving the rest of the kidney. It is preferred for many tumours confined to the kidney when complete removal is technically feasible. Preserving kidney tissue can be particularly important for someone with chronic kidney disease, a single functioning kidney, or tumours in both kidneys. [1, 2]
Radical nephrectomy removes the entire affected kidney. It may be appropriate for a larger or more complex tumour when partial nephrectomy would be unlikely to remove the cancer safely. Tumour size matters, but so does where the tumour sits. A small mass close to the main blood vessels or urine-collecting system can be more difficult to remove than a larger mass near the outer edge. [1, 2]
| If the scans show… | What the team may discuss |
|---|---|
| A small tumour that can be safely removed while preserving kidney tissue | Partial nephrectomy. |
| A small mass in someone for whom the benefits of immediate treatment may be limited | Active surveillance with planned scans and a clear explanation of what changes would prompt treatment. |
| A small tumour in someone for whom surgery carries substantial risk | Ablation, which destroys the tumour using heat or cold, after biopsy and review of the tumour’s location. |
| A large or complex tumour that cannot be safely removed with kidney-sparing surgery | Radical nephrectomy and how the remaining kidney is expected to function. |
4. How is locally advanced kidney cancer treated, and who needs treatment after surgery?
A kidney tumour can grow into nearby fat or extend into the renal vein or inferior vena cava without spreading to distant organs. This extension into a vein is called a tumour thrombus. Selected patients can still have surgery with the aim of cure. The level of vein involvement determines what the operation would involve and which surgical teams need to be involved. [1, 2]
After complete surgery, many patients move to surveillance with scans and kidney function checks. For selected patients with clear-cell RCC and a higher risk of recurrence, adjuvant pembrolizumab may be offered. This is immunotherapy given after surgery to reduce recurrence risk. The decision depends on the final pathology and the expected benefit in relation to possible immune-related side effects, some of which can persist after treatment ends. [1, 2]
The US FDA also approved belzutifan plus pembrolizumab in June 2026 for eligible adults with RCC containing a clear-cell component and intermediate-high or high risk of recurrence after surgery. This is a separate postoperative option. For treatment in Delhi, the applicable Indian prescribing indication and availability should be verified before it is recommended. [4]
5. How is metastatic kidney cancer treated?
When RCC has spread to distant organs, such as the lungs, bones, or liver, systemic therapy is usually the main treatment. In metastatic clear-cell RCC, first-line options often combine an immunotherapy drug with a targeted medicine. Examples include nivolumab plus cabozantinib, pembrolizumab plus axitinib, and pembrolizumab plus lenvatinib. A two-drug immunotherapy combination, nivolumab plus ipilimumab, is another option, particularly for patients with intermediate- or poor-risk disease. [1, 2]
The IMDC risk group helps guide treatment discussions for metastatic RCC. It is based on factors including how well someone is functioning day to day, blood test results, and the interval between diagnosis and the start of systemic treatment. The team also considers the RCC subtype, symptoms, other medical conditions, and any treatment previously given after surgery. [1, 2]
Does the kidney need to be removed if the cancer has spread? For many patients who need systemic treatment promptly, medicines come first. Kidney removal may be considered in selected cases, for example when the disease responds and delayed surgery has a clear purpose. Where there are only a few sites of spread, the team may also assess whether surgery or focused radiation to those sites could help. [1, 2]
What I look for clinically before recommending treatment
I review the scan images alongside the creatinine and estimated kidney function. For a small mass, I ask whether a biopsy would change the choice between surveillance, ablation, and surgery. If the tumour extends into a vein, I want to know how far it reaches and whether staging shows distant spread. After surgery, I review the actual pathology before recommending follow-up or immunotherapy. In metastatic disease, I ask what needs attention first, such as pain, bleeding, or disease that is progressing quickly, because that can determine the treatment sequence.
How the next step is decided
| If the reports show… | The next discussion is about… |
|---|---|
| A small kidney mass with uncertain features | Whether further imaging or biopsy would change management |
| A localised tumour suitable for kidney-sparing surgery | Partial nephrectomy and expected kidney function afterward |
| Tumour extending into a major vein without distant spread | Whether complete surgery is feasible and what expertise the operation requires |
| Higher-risk clear-cell RCC after complete removal | Surveillance versus postoperative treatment, including expected benefit and side effects |
| Distant spread | Systemic treatment first or, in selected cases, a role for surgery or focused radiation |
What to bring to a kidney cancer consultation in Delhi
- Kidney ultrasound, CT, or MRI reports, along with the original scan images.
- Reports and images from chest or other staging scans, if performed.
- Biopsy or nephrectomy pathology report, including subtype, stage, grade, and margins where reported.
- Recent creatinine and estimated kidney function results, including earlier readings if available.
- Details of previous surgery, ablation, immunotherapy, or targeted treatment.
- A note of current symptoms, relevant medical conditions, and any family history of kidney cancer.
Frequently asked questions
Does every kidney mass turn out to be cancer?
Some kidney masses are benign. Imaging can identify certain benign lesions, while others may need a biopsy or follow-up scans to clarify the diagnosis. [1, 2]
Can I live normally with one kidney after surgery?
Many people with a healthy remaining kidney live well after nephrectomy. Your starting kidney function and conditions such as diabetes or high blood pressure affect the outlook. Ask how kidney function and blood pressure will be monitored after surgery. [1, 2]
Is conventional chemotherapy used for kidney cancer?
For most clear-cell RCC, immunotherapy and targeted medicines are the main systemic treatments. Conventional chemotherapy has a role in certain rare kidney cancer subtypes, so the exact pathology matters. [1–3]
Does a tumour in the renal vein mean stage IV kidney cancer?
Extension into the renal vein can occur without distant spread. The full stage depends on the extent of local involvement and whether cancer has reached lymph nodes or distant organs. Some patients with vein involvement can still have surgery with the aim of cure. [1, 3]
Before deciding, ask your team to explain the exact subtype, whether the disease has spread, and how each option could affect your kidney function. If treatment after surgery is recommended, ask which finding puts you at higher risk of recurrence and how that changes the expected benefit.
This page is for general education. Individual treatment decisions require review of your scans, pathology, kidney function, and overall health by your treating team.
Clinical references
- European Association of Urology. EAU Guidelines on Renal Cell Carcinoma. 2026 edition.
- European Society for Medical Oncology. Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Diagnosis, Treatment and Follow-up of Patients With Renal Cell Carcinoma.
- National Cancer Institute. Renal Cell Cancer Treatment (PDQ), Patient Version.
- US Food and Drug Administration. FDA Approves Belzutifan With Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma. June 2026.